<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-zr-chp-en-dlbcl-li">
    <meta name="study:title" content="PB3267 - Pola-ZR-CHP in Extranodal DLBCL">
    <meta name="study:fileName" content="Abstracts/POLA-ZR-CHP-EN-DLBCL-LI-PB3267.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L/2L">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Zanubrutinib,BTK inhibitor,Rituximab,Monoclonal Antibody,Chemotherapy,CIT,Pola-ZR-CHP">

    <title>PB3267: Pola-ZR-CHP in Extranodal DLBCL (Li) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3267 - Pola-ZR-CHP in Extranodal DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                        <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=11)</h4>
                    <p>DLBCL Pts with extranodal (EN) involvement (1L/2L). Aim: Assess outcomes of Pola-ZR-CHP.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                        <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Pola-ZR-CHP)</h4>
                    <p>Polatuzumab + Zanubrutinib + R-CHP. Retrospective. Median 5 cycles.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (EOT, N=6)</h4>
                    <p>ORR: <span class="highlight-value">66.7%</span>CR: <span class="highlight-value">50%</span></p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Manageable (hematologic AEs). Promising for EN DLBCL. More data needed.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3267 - Outcomes of zanubrutinib combined with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-ZR-CHP) in the treatment of patients with extranodal (EN) diffuse large B-cell lymphoma (DLBCL) in a real-world setting</h1>
            <p class="abstract-sub-header">Caixia Li, Yuchen Hua, Sixun Jia, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3267 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Patients with multiple extranodal involvement diffuse large B-cell lymphoma (DLBCL) have a poor response rate to standard R-CHOP treatment.</li>
                        <li>This study assesses the outcomes of DLBCL patients treated with Zanubrutinib in combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-ZR-CHP) as either first- or second-line therapy.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To assess the outcomes of DLBCL patients treated with Zanubrutinib in combination with Pola-R-CHP as either first- or second-line therapy in a real-world setting.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Single-center, retrospective study.</li>
                        <li>Institution: First Affiliated Hospital of Soochow University.</li>
                        <li>Patient Population: Adult patients (aged ≥18 years) diagnosed with DLBCL, who received Pola-ZR-CHP between August 2023 and January 2025 as first- or second-line therapy.</li>
                        <li>Treatment Regimen: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-ZR-CHP). (Specific dosing for Zanubrutinib or Pola-R-CHP components not detailed in abstract).
                        <li>Endpoints: Overall response rate (ORR), complete response (CR) rate (Lugano criteria), and progression-free survival (PFS).</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Pola-ZR-CHP Treatment in Extranodal DLBCL</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=11)</strong>
                            <span>EN DLBCL (1L or 2L)</span>
                            <span>First Affiliated Hospital of Soochow University</span>
                            <span>(Aug 2023 - Jan 2025)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%;">
                                <strong>Treatment: Pola-ZR-CHP</strong>
                                <span>(Polatuzumab Vedotin, Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone)</span>
                                <span>Median 5 cycles (range 1-6)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Response (ORR, CRR - Lugano)</span>
                           <span>Progression-Free Survival (PFS)</span>
                           <span>Safety (Adverse Events)</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=11)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>53 (22-76)</td></tr>
                                <tr><td>Male, n (%)</td><td>6 (54.5%)</td></tr>
                                <tr><td>Treatment Line</td><td></td></tr>
                                <tr><td class="pl-4">First-line (Untreated)</td><td>9 (81.8%)</td></tr>
                                <tr><td class="pl-4">Second-line (R/R)</td><td>2 (18.2%)</td></tr>
                                <tr><td>Ann Arbor Stage III/IV, n (%)</td><td>11 (100%)</td></tr>
                                <tr><td>IPI Score ≥3, n (%)</td><td>9 (81.8%)</td></tr>
                                <tr><td>Extranodal Involvement, n (%)</td><td>11 (100%)</td></tr>
                                <tr><td class="pl-4">Sites Involved</td><td>Liver, adrenal glands, GI tract, pleura</td></tr>
                                <tr><td class="pl-4">≥2 Extranodal Sites, n</td><td>8</td></tr>
                                <tr><td>Elevated LDH, n</td><td>6</td></tr>
                                <tr><td>Non-GCB Subtype (Hans), n</td><td>10</td></tr>
                                <tr><td>Double-Expressor Lymphoma, n</td><td>5</td></tr>
                                <tr><td>TP53 Mutations (tested N=5), n</td><td>2</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median F/U: 6 months)</h2>
                    <p class="text-sm mb-2">All patients completed ≥1 cycle of Pola-ZR-CHP; median 5 cycles (range 1-6). Total 47 cycles administered.</p>
                    <h3 class="abstract-sub-section-title mt-2">Response After 3 Cycles (N=9 evaluable)</h3>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>ORR: 100% (9/9)</li>
                        <li>CR Rate: 33% (3/9)</li>
                    </ul>
                    <h3 class="abstract-sub-section-title mt-3">Response at End of Treatment (EOT, N=6 evaluable)</h3>
                    <div class="chart-container mb-3">
                        <svg id="polaZrChpEotResponseChart" width="300" height="280"></svg>
                        <div id="polaZrChpEotResponseLegend" class="legend"></div>
                    </div>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>All TP53 unmutated patients achieved remission.</li>
                        <li>One of two TP53 mutated patients experienced disease progression.</li>
                        <li>Disease progression occurred in 2 patients overall. Two patients died.</li>
                        <li>Estimated Median PFS: 27.5 months.</li>
                        <li>Estimated 12-month PFS Rate: 66.7%.</li>
                    </ul>
                     <div class="km-plot-container zoomable-image-container mt-4">
                        <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/POLA-ZR-CHP-EN-DLBCL-LI-PB3267_Figure1_PFS_OS.png" alt="Kaplan-Meier curves for PFS and OS" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/600x300/E0F2F7/0A2F5C?text=PFS/OS+Curves+Not+Available';">
                        <p class="text-xs text-center mt-1">Progression-Free Survival (PFS) and Overall Survival (OS) (Adapted from Abstract Image)</p>
                    </div>
                </div>


                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=11)</h2>
                    <p class="text-sm">The Pola-ZR-CHP regimen was generally well-tolerated.</p>
                    <p class="text-sm mt-2"><strong>Most Common Adverse Events (AEs):</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mt-1">
                        <li>Hematologic toxicities were most common.</li>
                        <li>Neutropenia: 7 patients.</li>
                        <li>Thrombocytopenia: 5 patients.</li>
                        <li>Pneumonia: 4 patients.</li>
                        <li>No treatment-related deaths were observed.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>The combination of Zanubrutinib and Pola-R-CHP demonstrates promising efficacy and good safety in both previously untreated and R/R extranodal DLBCL patients.</li>
                <li>These findings suggest that Pola-ZR-CHP may offer significant survival benefits for this patient population.</li>
                <li>Further studies with larger cohorts and extended follow-up are warranted to validate these results and explore the long-term outcomes of this novel therapeutic regimen.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AE, Adverse Event; ADC, Antibody-Drug Conjugate; CR, Complete Remission; CIT, Chemoimmunotherapy; DLBCL, Diffuse Large B-Cell Lymphoma; EN, Extranodal; EOT, End of Treatment; F/U, Follow-up; GCB, Germinal Center B-cell like; GI, Gastrointestinal; IPI, International Prognostic Index; LDH, Lactate Dehydrogenase; LOT, Lines of Therapy; NHL, Non-Hodgkin Lymphoma; ORR, Overall Response Rate; OS, Overall Survival; PD, Progressive Disease; PFS, Progression-Free Survival; Pola, Polatuzumab Vedotin; Pola-R-CHP, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; Pola-ZR-CHP, Polatuzumab Vedotin, Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; R, Rituximab; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; R/R, Relapsed/Refractory; TP53, Tumor Protein 53.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Li C, Hua Y, Jia S, et al. Outcomes of zanubrutinib combined with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-ZR-CHP) in the treatment of patients with extranodal (EN) diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Abstract #PB3267 presented at European Haematology Association (EHA) Congress. 12–15 June 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3267 | Abstract Release: 05/14/25 | Publication Only Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawPolaZrChpEotResponseChart(containerId, legendContainerId) {
            const chartData = {
                keys: ["CR", "PR", "Other (SD/PD/NR)"],
                values: {
                    CR: 50.0,      // 3/6
                    PR: 16.7,      // ORR 66.7% (4/6) - CR 50% (3/6) = PR 16.7% (1/6)
                    "Other (SD/PD/NR)": 33.3 // 2/6 did not respond (100% - 66.7% ORR)
                },
                colors: ["var(--sobi-teal)", "var(--sobi-yellow)", "var(--sobi-medium-gray-text)"],
                orr: 66.7
            };
            const chartTitle = "Response at End of Treatment (N=6 Evaluable)";

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 300;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.80, 250);
            }

            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 40, right: 20, bottom: 30, left: 50 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <= 0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const categories = ["Response"];
            const stack = d3.stack().keys(chartData.keys.filter(key => chartData.values[key] > 0));
            const stackedData = stack([chartData.values]);

            const xScale = d3.scaleBand()
                .domain(categories)
                .range([0, chartWidth])
                .padding(0.7);

            const yScale = d3.scaleLinear()
                .domain([0, 100])
                .range([chartHeight, 0]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale).tickValues([]))
                .select(".domain").remove();

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");

            g.append("g")
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "var(--sobi-card-border)")
                .style("stroke-opacity", "0.7");

            const color = d3.scaleOrdinal()
                .domain(chartData.keys)
                .range(chartData.colors);

            g.selectAll(".serie")
                .data(stackedData)
                .enter().append("g")
                .attr("class", "serie")
                .selectAll("rect")
                .data(d => d)
                .enter().append("rect")
                .attr("x", d => xScale(categories[0]))
                .attr("y", d => yScale(d[1]))
                .attr("height", d => Math.max(0, yScale(d[0]) - yScale(d[1])))
                .attr("width", xScale.bandwidth())
                .attr("fill", (d, i, nodes) => {
                    const seriesKey = d3.select(nodes[i].parentNode).datum().key;
                    return color(seriesKey);
                })
                .attr("rx", 3).attr("ry", 3);

            stackedData.forEach((series) => {
                series.forEach((d) => {
                    const y0 = d[0];
                    const y1 = d[1];
                    const percentage = y1 - y0;
                    if (percentage > 4) {
                        g.append("text")
                            .attr("class", "chart-label")
                            .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                            .attr("y", yScale(y0 + percentage / 2) + 4)
                            .attr("text-anchor", "middle")
                            .style("fill", (series.key === "CR" && percentage > 15) ? "white" : "var(--sobi-dark-text)")
                            .style("font-size", "10px")
                            .style("font-weight", "bold")
                            .text(`${percentage.toFixed(1)}%`);
                    }
                });
            });

            if (chartData.orr) {
                g.append("text")
                    .attr("class", "chart-label orr-label")
                    .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                    .attr("y", yScale(chartData.orr) - 8)
                    .attr("text-anchor", "middle")
                    .style("font-weight", "600")
                    .style("font-size", "10px")
                    .style("fill", "var(--sobi-dark-blue)")
                    .text(`ORR: ${chartData.orr.toFixed(1)}%`);
            }

            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2 + 5)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = chartData.keys.filter(key => chartData.values[key] > 0).map(key => ({
                label: `${key} (${chartData.values[key].toFixed(1)}%)`,
                color: color(key)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }

        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawPolaZrChpEotChart = debounce(() => drawPolaZrChpEotResponseChart("#polaZrChpEotResponseChart", "#polaZrChpEotResponseLegend"), 250);

        window.addEventListener('resize', debouncedDrawPolaZrChpEotChart);

        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawPolaZrChpEotChart();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawPolaZrChpEotChart, 0);
        }
    </script>
</body>
</html>